Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review

Bibliographic Details
Published in:	eJHaem
Main Authors:	Solo Traoré, Mehdi Roumila, Pirayeh Eftekhari, Hassan Farhat, Fatiha Merabet, Oumar Guira, Philippe Rousselot, Reza Azarian, Caroline Besson
Format:	Article
Language:	English
Published:	Wiley 2020-11-01
Online Access:	https://doi.org/10.1002/jha2.80

Similar Items

Diabetes knowledge and associated factors in adolescents and young adults with type 1 diabetes in Ouagadougou (Burkina Faso)
by: Daniel Zemba, et al.
Published: (2023-09-01)

Drug review: Ibrutinib
by: Parathan Karunakaran
Published: (2020-01-01)

How to use ibrutinib
by: Е. А. Nikitin, et al.
Published: (2017-04-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells
by: Fengbo Jin, et al.
Published: (2024-10-01)

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
by: Gellért Balázs Karvaly, et al.
Published: (2022-07-01)

High stress related to COVID-19 among health workers in the Plateau Central healthcare region (BURKINA FASO): a cross-sectional study
by: Solo Traoré, et al.
Published: (2023-06-01)

Development and Characterization of Ibrutinib-Loaded Ethylcellulose-Based Nanosponges: Cytotoxicity Assay against MCF-7 Cell Lines
by: Farhat Fatima, et al.
Published: (2023-04-01)

Ibrutinib-induced pulmonary angiotensin-converting enzyme activation promotes atrial fibrillation in rats
by: Sen Yan, et al.
Published: (2024-02-01)

Neumonitis inducida por ibrutinib
by: Carmen Gil Barroso, et al.
Published: (2025-10-01)

Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01)

Ibrutinib-associated osteonecrosis of the jaw
by: Annu Singh, et al.
Published: (2024-03-01)

Ibrutinib and Neurolisteriosis: Simple Coincidence?
by: Paul Dalmas, et al.
Published: (2024-06-01)

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
by: Milena Kohn, et al.
Published: (2021-11-01)

Pulmonary Thromboembolism in Multidrug-Resistant Tuberculosis: A Case Series Highlighting the Importance of Early Diagnosis and Management
by: Vikas Marwah, et al.
Published: (2023-12-01)

A convolutional neural network highlights mutations relevant to antimicrobial resistance in Mycobacterium tuberculosis
by: Anna G. Green, et al.
Published: (2022-07-01)

Profound Sinoatrial Arrest Associated with Ibrutinib
by: Kanupriya Mathur, et al.
Published: (2017-01-01)

Recall of ibrutinib and issues with therapeutic approval
by: Alyson Haslam, et al.
Published: (2024-08-01)

Ibrutinib and the chemotactic lymph node choreography
by: Tanja N. Hartmann
Published: (2023-08-01)

Invasive Aspergillosis in Patients Treated With Ibrutinib
by: Moritz Fürstenau, et al.
Published: (2020-04-01)

Electrocardiographic Changes Associated With Ibrutinib Exposure
by: Michael G. Fradley MD, et al.
Published: (2020-06-01)

Ibrutinib: A narrative drug review
by: Pritesh Naresh Munot, et al.
Published: (2020-01-01)

Prevalence of undiagnosed diabetes mellitus and its associated factors in urban Burkina Faso
by: Solo Traoré, et al.
Published: (2024-09-01)

Recent advances in pulmonary tuberculosis, the application of deep learning to medical topics, and highlights from this issue of Ewha Medical Journal
by: Hae-Sun Chung
Published: (2025-04-01)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01)

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01)

Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)

Cutaneous Lymphocytic Vasculitis Due to Ibrutinib Therapy
by: D. Rodriguez-Baeza, et al.
Published: (2024-11-01)

Rhythm and Conduction Disorders in Patients Receiving Ibrutinib
by: EI Emelina, et al.
Published: (2019-03-01)

Rare but Serious: Ibrutinib Induced Liver Failure
by: Fleur S. Kleijwegt, et al.
Published: (2019-12-01)

From antibiotics to ibrutinib: An array of treatment modalities
by: Catherine Thieblemont
Published: (2018-06-01)

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia
by: Jorge J. Castillo, et al.
Published: (2018-07-01)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
by: Christoph Kornauth, et al.
Published: (2021-02-01)

Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma
by: Kaleigh E. Lindholm, et al.
Published: (2021-08-01)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
by: Fangmin Huang, et al.
Published: (2023-09-01)

IBRUTINIB RELATED NEUROPATHY: A CASE REPORT
by: Zeynep Tuğba Güven, et al.
Published: (2023-10-01)

Ibrutinib-associated pityriasis rosea–like rash
by: Carole Bitar, MD, et al.
Published: (2018-01-01)

Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
by: Dong R, et al.
Published: (2022-09-01)

Delayed onset of ibrutinib-related posterior uveitis
by: Efthymia Kalogera, et al.
Published: (2026-04-01)

Recurrent Cellulitis Revealing Helicobacter cinaedi in Patient on Ibrutinib Therapy, France
by: Anne-Laure Roupie, et al.
Published: (2023-03-01)